Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: A multicentre phase II trial

被引:3
作者
Kuhfahl, J
Steinbrecher, C
Wagner, T
Wagner, H
Fritze, D
Link, H
Schulte, F
Pichlmeier, U
Kreuser, ED
机构
[1] Krankenhaus Barmherzige Bruder, Klin Internist Onkol & Hamatol, Regensburg, Germany
[2] Med Univ Lubeck, Med Klin 1, D-23538 Lubeck, Germany
[3] Klinikum Weiden, Med Klin 1, Weiden, Germany
[4] Klinikum Darmstadt, Med Klin 5, Darmstadt, Germany
[5] Klinikum Kaiserslautern, Med Klin 1, Kaiserslautern, Germany
[6] medac GmbH, Wedel, Germany
来源
ONKOLOGIE | 2004年 / 27卷 / 05期
关键词
colorectal cancer; 5-fluorouracil; sodium folinate; 24-hour infusion; weekly; second-line treatment;
D O I
10.1159/000080365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and second-line treatment in advanced metastatic colorectal cancer. Substitution of CA-FA by the new formulation sodium folinate (S-FA) allows the simultaneous i.v. administration of folinic acid with 5-FU in one pump. Patients and Methods: From 1999 to 2001, 42 patients with metastatic colorectal cancer after pre-treatment with a 5-FU bolus regimen were recruited in 5 centres to receive weekly 24-h infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as second-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 106 6-week cycles (median 2, range 1-6 per patient) were administered during the study. The median follow-up was 22 months. Out of 42 patients, 1 (2%) achieved complete remission, 3 (7%) partial remission, and 31 (74%) no change. Median time to tumour progression was 5.7 months (95% CI: 4.1-6.5). The median survival was reached at 14.7 months (95% CI: 11.0-22.0). Among major toxicities, NCI-CTC grade III/IV diarrhoea occurred in 8/42 (19%), grade III hand-foot-syndrome in 5/42 (12%) and grade III/IV stomatitis in 3/ 42 (7%) patients. Conclusion: Similar to conventional 24-h 5-FU + CA-FA treatment, the combination with S-FA in second-line therapy induced 9% objective responses and stopped tumour progression in 74%. The simultaneous administration of both, S-FA and 5-FU over 24 h dissolved in one pump is convenient, safe and effective as second-line treatment for patients with colorectal cancer.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 27 条
[1]   A PHASE-II STUDY OF WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE FLUOROURACIL WITH LEUCOVORIN IN COLORECTAL-CARCINOMA [J].
ARDALAN, B ;
CHUA, L ;
TIAN, EM ;
REDDY, R ;
SRIDHAR, K ;
BENEDETTO, P ;
RICHMAN, S ;
LEGASPI, A ;
WALDMAN, S ;
MORRELL, L ;
FEUN, L ;
SAVARAJ, N ;
LIVINGSTONE, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :625-630
[2]   Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate [J].
Bruch, HR ;
Esser, M .
ONKOLOGIE, 2003, 26 (05) :469-472
[3]   Oxaliplatin - A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies [J].
Culy, CR ;
Clemett, D ;
Wiseman, LR .
DRUGS, 2000, 60 (04) :895-924
[4]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[5]   Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer?: A phase II study [J].
Hartmann, JT ;
Köhne, CH ;
Schmoll, HJ ;
Daikeler, T ;
Kanz, L ;
Bokemeyer, C .
ONCOLOGY, 1998, 55 (04) :320-325
[6]   Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer [J].
Hartung, G ;
Hofheinz, RD ;
Wein, A ;
Riedel, C ;
Rost, A ;
Fritze, D ;
Kreuser, ED ;
Drees, M ;
Kühnel, J ;
Hehlmann, R ;
Queisser, W .
ONKOLOGIE, 2001, 24 (05) :457-462
[7]   FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666
[8]   HIGH-DOSE 5-FLUOROURACIL (5-FU) AND FOLINIC ACID IN ADVANCED COLORECTAL SITES OF DISEASE CANCER RESISTANT TO STANDARD-DOSE LOCAL 5-FU TREATMENT - RESULTS OF A LIVER PHASE-II STUDY [J].
JAGER, E ;
KLEIN, O ;
WACHTER, B ;
MULLER, B ;
BRAUN, U ;
KNUTH, A .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) :1717-1717
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine:: the Jena experience in 79 patients [J].
Kliche, KO ;
Kubsch, K ;
Raida, M ;
Masri-Zada, R ;
Höffken, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (09) :516-524